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Genome-wide RNA interference (RNAi) screening is an emerging and powerful technique for genetic screens, which
can be divided into arrayed RNAi screen and pooled RNAi screen/selection based on different screening strategies.
To date, several genome-wide RNAi screens have been successfully performed to identify host factors essential for
influenza virus replication. However, the host factors identified by different research groups are not always consistent.
Taking influenza virus screens as an example, we found that a number of screening parameters may directly or
indirectly influence the primary hits identified by the screens. This review highlights the differences among the
published genome-wide screening approaches and offers recommendations for performing a good pooled shRNA
screen/selection.
Keywords: RNA interference (RNAi), Genome-wide screen, Arrayed siRNA screen, Pooled shRNA screen, Influenza virus,
LentivirusIntroduction
RNA interference (RNAi) is a revolutionary technique
for studying the biological functions of a particular gene
by silencing its gene expression that can be applied in
mammalian systems. The manipulation of gene expres-
sion of any particular gene by RNAi provides insight into
the genetic networks related to the target gene. Thus far,
the main approaches for RNAi screening can be divided
into two screening formats, arrayed screen and pooled
selection/screen. For arrayed screen, each RNAi reagent
is assigned to a unique well in a microplate, and a variety
of cell-based assays are performed in the microplate for-
mat. After the assay, cells with significant changes can
be identified and the related RNAi reagents can be
traced by using a database. For pooled selection/screen,
all of the RNAi reagents are pooled together and added
randomly to cells. There are two strategies for pooled se-
lection: positive selection, which only detects surviving
cells and does not require an untreated control, and
negative selection, which includes an untreated control* Correspondence: t23514@mail.cmuh.org.tw
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unless otherwise stated.for comparison to allow the detection of RNAi reagents
that make the cells resistant or sensitive to the selective
reagent. The significant RNAi reagents are subsequently
deconvoluted by using Next Generation Sequencing (NGS)
or barcode microarray.
Influenza virus causes annual epidemics and recurring
pandemics which potentially threaten public health and
the global economy. Influenza A viruses (IAVs) are envel-
oped RNA viruses with single-stranded, negative-sense
viral RNAs encoding 11 viral proteins [1]. Two of the viral
proteins, neuraminidase (NA) and matrix protein 2 (M2),
are the targets of the currently-used antiviral drugs. How-
ever, the high error rate of the viral RNA-dependent RNA
polymerase (RdRp) leads to rapid changes in these two
proteins and generation of drug-resistant influenza viruses.
It has been widely recognized that the replication of influ-
enza virus relies on host factors and cellular machinery to
complete its life cycle. Accordingly, identification of the
host factors involved in viral replication is of interest to
understand the mechanisms of the virus replication cycle
more comprehensively and to find new targets for the de-
velopment of antiviral compounds. Several genome-wide
RNAi screens (summarized in Table 1) have been con-
ducted for influenza virus to identify host factors required
for influenza virus replication and provide robust informa-
tion regarding the screening method. Here, we reviewhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Table 1 Genome-wide RNAi screens in influenza virus research (2008–2013)
Hao et al. (2008) [2] Brass et al. (2009) [3] Shapira et al. (2009) [4] Kŏnig et al. (2010) [5] Karlas et al. (2010) [6] Su et al. (2013) [7] Tran et al. (2013) [9]
No. of genes screened 13,071 17,877 1,745 (pre-selected by
yeast −2-hybrid and
microarray)
19,628 22,843 16,368 21,415
Primary screen















Delivery method Bathing Transfection Transfection Transfection Transfection Lentiviral Lentiviral
Cell used for screen
(Origin)
DL1 cells (Drosophila) U2OS cells (Human) HBEC cells (Human) A549 cells (Human) A549/293 T cells
(Human)
A549 cells (Human) A549 cells (Human)


















































two or more siRNAs
targeting to one gene
NA Biological replicates/
two or more siRNAs
targeting to one gene
Two or more siRNAs
targeting to one gene
Two or more siRNAs
targeting to one gene
Biological replicates
No. of candidate genes
(Primary screen)
110 133 616 295 287 110 138











































No. of candidate genes
(Secondary screens)
NA NA NA 219 168 38 ~2/3 of 138 candidate
genes
Steps in the viral life
cycle covered by the
secondary screen
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the different screening approaches and the screening re-
sults obtained from these screens.
Genome-wide arrayed RNAi screens for the identification
of host factors affecting influenza virus replication
The first genome-wide RNAi screen for the identifica-
tion of host factors required for influenza virus replica-
tion was performed in a Drosophila cell line by Hao
et al. [2] in 2008, when the RNAi-based screening was
not yet well established in the mammalian system. To
bypass the entry block of wild-type influenza virus into
Drosophila cells, the authors generated a recombinant
A/WSN/33 virus possessing vesicular stomatitis virus
glycoprotein G (VSV-G) as a viral envelope protein to
mediate its entry into target cells and carrying renilla lu-
ciferase gene as a reporter to assess the efficiency of
virus RNA replication. A dsRNA library targeting 13,071
Drosophila genes was arrayed into 384-well microplates
and applied for screening the host factors which modu-
late influenza virus RNA replication. A total of 110 can-
didate genes were identified by this screen, three of
which (corresponding human orthologs; ATP6V0D1,
COX6A1 and NXF1) had been validated to play critical
roles in the replication of H5N1 and H1N1 influenza A
viruses in mammalian cells. This study set up a framework
for genome-wide RNAi screening to identify unknown
host factors required for influenza virus replication.
In 2009, Brass et al. [3] performed a genome-wide
arrayed RNAi screen (17,877 genes; Dharmacon) in hu-
man U2OS cells and identified 133 host factors required
for influenza virus replication as evidenced by the alter-
ation of HA expression on the cell surface. In this study,
the candidate genes were selected based on the criteria that
the gene was knocked down by at least 2 unique siRNAs
to minimize the probability of off-target effects. Three
interferon-inducible transmembrane proteins (IFITM1,
IFITM2 and IFITM3) were identified to be antiviral restric-
tion factors during virus infection. Shapira et al. [4] used a
pre-selected gene list (1,745 genes) based on integrated
yeast two-hybrid and microarray data, which were ob-
tained from influenza-related studies, to identify cellular
modifiers of influenza virus replication in human HBEC
cells. The authors identified 616 host factors that were
proposed to be involved in modulation of virus replication
and/or interferon production.
König et al. [5] and Karlas et al. [6] also utilized a
modified genome-wide RNAi screening approach by
using an arrayed siRNA library (Qiagen). König et al.
generated recombinant influenza virus possessing renilla
luciferase gene for the primary screen, and identified
295 host factors out of the 19,628 genes in mammalian
cells. Among the 295 candidate genes, 219 host factors
were further confirmed to be essential for efficientreplication of the wild-type influenza virus (A/WSN/33)
in human A549 cells. On the other hand, Karlas et al.
took a two-step strategy to survey host factors involved
in influenza virus replication. In the first step, A549 cells
were transfected with siRNA, and then infected with
wild-type influenza virus (A/WSN/33). In the second
step, the virus supernatants were collected and used to
challenge HEK293T carrying an influenza virus-driven
luciferase reporter for primary screen. After screening of
an arrayed RNAi library (22,843 genes), a total of 287 genes
were identified as primary hits. The secondary screen was
performed by using A/WSN/33 and A/Hamburg/04/2009
independently, and 168 out of the 287 primary hits were
validated to modulate influenza virus replication. Notably,
72 of them were common host factors affecting the repli-
cation of both influenza virus strains.
Genome-wide pooled RNAi screens applied to identify
host factors required for influenza virus replication
Rather than performing the arrayed RNAi screens
(dsRNA or siRNA) as mentioned above, we established a
genome-wide pooled RNAi screen (lentiviral shRNA ex-
pression system) based on a positive selection strategy to
identify host factors required for influenza virus replica-
tion [7]. Under positive (survival) selection, cells with
gene knockdown that provide resistance to influenza
virus-induced cell death were selected and enriched in
the population during pooled RNAi selection. The in-
crease of the resistant cells in the population makes
identification of the contents of shRNAs possible. In
brief, A549 cells were infected with the pooled lentivi-
ruses (multiplicity of infection; MOI = 0.3) generated
from a genome-wide RNAi library from the RNAi con-
sortium (TRC) [8], and subsequently challenged with
influenza virus (A/WSN/33) at a cytotoxic dose. The
surviving A549 cells were collected and subjected to
deep sequencing to identify the embedded shRNA(s)
that silenced host genes and protected cells from influ-
enza virus-induced cell death. Ideally, host genes identi-
fied by this positive selection should be the essential
factors supporting influenza virus replication. Out of the
16,368 genes screened, a total of 110 host genes targeted
by at least two unique shRNA per gene were identified
as our primary hits. The expression levels of these hits
in A549 cells were further confirmed by EST or micro-
array analyses. We next carried out a high content
image-based screen as a secondary screen and found
that at least 38 candidate genes were involved in the
early stages of the virus life cycle. Among them, E3 ubiqui-
tin ligase Itch was proven to be an essential host factor for
influenza virus “uncoating” [9]. Thus, we concluded that
the genome-wide pooled RNAi screen via positive selec-
tion is a useful RNAi screen method for exploring host
factors of lytic viruses.
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screening approach, by using a higher influenza virus
dose with a shorter infection time, to explore specific
host genes required for influenza virus-induced cell
death. A genome-wide pooled RNAi library (Thermo
Scientific Open Biosystems; also known as an RNAi library
from the Hannon and Elledge Lab) targeting 21,415 host
genes were screened and a total of 138 host genes were
identified to be involved in influenza virus (A/NY/55/
2004) replication. The authors validated these hits and
identified APRIL, TWE-PRIL and USP47 as essential host
factors for supporting influenza viral replication.
Comparing host factors involved in influenza virus
replication among different genome-wide RNAi screens
A total of 1,362 host factors were identified as potential
cellular mediators in relation to influenza virus replica-
tion by the seven aforementioned RNAi screens. More
than 90% of the hits (1,229 genes) were identified by
only one of the RNAi screens. 113 overlapping host
genes were identified in two independent RNAi screens,
14 overlapping genes (ARCN1, ATP6V0B, ATP6V1B2,
COPB2, MAPK13, NUP98, PGD, PRPF8, RAB5A, RNF44,
RPS10, RPS16, STARD5 and TRIM21) were identified in
three RNAi screens, and 6 overlapping genes (ATP6AP1,
ATP6V0C, ATP6V0D1, COPA, COPG and NXF1) were
identified in four individual screens (Table 2). However, no
host factors were commonly identified in all seven screens.
Among the overlapping hits, many mapped to modulation
of specific steps of the influenza virus life cycle, such as
endocytosis (e.g., RAB5A) [10]; COPI vesicular transport
(e.g., ARCN1, COPA, COPB2 and COPG) [11]; V-type
ATPase proton transport (e.g., ATP6AP1, ATP6V0B,
ATP6V0C, ATP6V0D1 and ATP6V1B2) [12]; nuclear im-
port (e.g., NUP98) [13]; pre-mRNA splicing (e.g., PRPF8);
nuclear export (e.g., NXF1) [14]; and protein translation
(e.g., RPS10 and RPS16). Therefore, genome-wide RNAi
screens apparently constitute a reliable approach to iden-
tify authentic host factors involved in influenza virus repli-
cation, but these screens also possess some intrinsic
difficulties that may hinder the design of an ideal screen-
ing procedure.
Factors that lead to successful identification of specific
host factors by RNAi screens
Only a limited number of overlapping host factors were
identified among these RNAi screens, suggesting that
the parameters used in the different RNAi screening
protocols likely affect the screening results. Relevant pa-
rameters may include: (i) characteristics of influenza
virus (virus strain, virus quality, viral subtype, prototype
or recombinant virus) and host cell line (cell type, cell
quality, genetic profile); (ii) features of the RNAi library
screened, particularly the knockdown efficiency of theRNAi resources, and the quality of the RNAi library; (iii)
screening method/time points for analysis; and (iv) hit-
selection criteria and evaluation of proper controls, e.g.,
at least two siRNAs or shRNAs targeting to the same
gene, and z-score of RNAi screen. Screens that used
similar screening resources or approaches showed a
higher degree of concordance. For example, Brass et al.
and Shapira et al. used the same source of siRNA library
(Dharmacon) and influenza virus strain (A/Puerto Rico/
8/34) for arrayed siRNA screens, and in their lists of pri-
mary gene hits there were 16 overlapping host factors.
Similarly, König et al. and Karlas et al. used the same
siRNA library (Qiagen) and influenza virus strain (A/
WSN/33) for arrayed siRNA screens and identified 25
overlapping host factors (Table 3). Moreover, the steps
of influenza virus replication covered by RNAi screening
may determine the populations of host factors identified
in the primary screens. For example, Shapira et al. and
Tran et al. performed RNAi screens aiming at the entire
viral life cycle; 24 overlapping host factors were identi-
fied in their primary hits (Table 3). It is also noteworthy
that both groups analyzed the results at similar time
points (2–3 days) after influenza virus infection. On the
other hand, our screen strategy was based on cell sur-
vival and analyzed the hits at a later time point (4 weeks)
after influenza virus infection [7]. Under such stringent
selection conditions, some host factors targeted by ef-
fective shRNAs, such as factors for cell survival or cell
proliferation, are likely completely excluded from our
primary hits after long-term selection; as a result, our hit
list includes fewer overlaps with those identified by other
RNAi screens. Nonetheless, the hits identified are more
likely to represent better drug targets as compared to
those identified by the arrayed siRNA screens (see ex-
planation below). Thus, both the arrayed and the pooled
RNAi library screening procedures are able to identify
specific host factors for viral replication. (A list of all
candidate genes from each screen and overlapping genes
from respective screens is available upon request).
Differences between arrayed RNAi screening and pooled
RNAi screen/selection
So far, most of the reported studies have used an arrayed
siRNA library. An assay with quantitative characteristics,
such as reporter assay or detecting viral protein expres-
sion, is a common strategy for identification of host fac-
tors using the arrayed RNAi screens. After silencing by the
arrayed siRNA, the reduction of reporter activity (or the
decrease in viral protein expression) reveals the host fac-
tor(s) essential for supporting influenza virus replication.
Although several virus replication-related host factors
have been successfully identified by the genome-wide
arrayed RNAi screens, the high-cost of the siRNA library
and the requirement for a robotic liquid handling system
Table 2 Gene symbols and numbers of overlapping hits








ATP6AP1 4 CLOCK 2 PHF2 2
ATP6V0C 4 COPB1 2 PHF3 2
ATP6V0D1 4 DAPK2 2 PLK3 2
COPA 4 DCLRE1A 2 PLXNA2 2
COPG 4 DCLRE1C 2 PNMA1 2
NXF1 4 DHCR24 2 POLD3 2
ARNC1 3 DLG5 2 PPAN 2
ATP6V0B 3 DPF2 2 PPARA 2
ATP6V1B2 3 EIF2AK2 2 PPP1R14D 2
COPB2 3 EIF4A2 2 PPP2R2D 2
MAPK13 3 EPHA7 2 PQLC1 2
NUP98 3 EPHB2 2 PRKACA 2
PGD 3 ERCC4 2 PSENEN 2
PRPF8 3 FAM38A 2 PSMD11 2
RAB5A 3 FAU 2 PSMD14 2
RNF44 3 FGFR2 2 PTPN6 2
RPS10 3 FLNC 2 PTPRN 2
RPS16 3 HIST1H2AC 2 PTS 2
STARD5 3 HRAS 2 RAB10 2
TRIM21 3 IFIT5 2 RACGAP1 2
ABCC10 2 IGSF1 2 RIOK3 2
APOBEC3G 2 IKBKE 2 RP2 2
ARTN 2 IL17RA 2 RPL13A 2
ATF1 2 IL1A 2 RPS14 2
ATP6AP2 2 IRF2 2 RPS20 2
ATP6V1A 2 ISG15 2 RPS4X 2
B2M 2 IVNS1ABP 2 RPS5 2
BPTF 2 JUN 2 RRP1B 2
BUB3 2 KPNB1 2 RUNX1 2
BZRAP1 2 KRTCAP2 2 SAMHD1 2
C14orf109 2 MADD 2 SELPLG 2
C21orf33 2 MAP2K3 2 SF3A1 2
C5orf38 2 MAP3K12 2 SF3B1 2
C6orf62 2 MDM2 2 SIGMAR1 2
CALCOCO2 2 MED6 2 SLC1A3 2
CAMK2B 2 MFAP1 2 SNRP70 2
CCL13 2 MPG 2 SUPT6H 2
CD81 2 MYC 2 TCF7L2 2
CDC42BPA 2 NHP2L1 2 TNFRSF18 2
CDKN2AIP 2 NR4A2 2 TNK2 2
CFLAR 2 OSMR 2 TOPORS 2
Table 2 Gene symbols and numbers of overlapping hits
identified by RNAi screens (Continued)
CLEC2B 2 P2RY12 2 TRIM28 2
CLIC4 2 PAGE5 2 VCP 2
CLK1 2 PDGFRA 2 WTAP 2
ZNF154 2
Chou et al. Journal of Clinical Bioinformatics  (2015) 5:2 Page 5 of 9for high throughput screening are two major drawbacks
of this approach. In addition, the duration of gene silen-
cing by siRNA transfection usually lasts for less than
1 week, which limits the usage of siRNA-based screen if
long-term knockdown is needed. The lentivirus-based
arrayed RNAi screen or pooled RNAi screen, on the
other hand, can overcome the short-term effect of
siRNA to discover host factors crucial for influenza virus
replication. However, the much higher cost (compared
to an siRNA library) and the requirement for a robotic
liquid handling system for genome-wide arrayed shRNA
screen are again major concerns. On the other hand, the
cost of the pooled RNAi reagent is much lower and
screen/selection can be conducted in most laboratories.
We performed a genome-wide pooled RNAi screen
and identified host factors using a survival-dependent
screening strategy [7]. Influenza virus infection induces
cell apoptosis in certain cell types [15-17], giving the
theoretical basis for our positive selection strategy for
the pooled RNAi screen. Taking advantage of inhibition
of the lytic cycle of influenza virus by RNAi, we selected
the surviving cells with specific genes knocked down by
RNAi and identified the essential host factors required
for influenza virus replication. In theory, using survival
rate as a phenotypic change should be able to be applied
to an arrayed siRNA screen; however, the window of op-
portunity for measurement is narrow making it difficult to
determine hits. On the contrary, the genome-integration
property of lentivirus-based shRNA expression maintains
host gene knockdown over a long period of time; thus,
there is plenty of time to select cells refractory to the cyto-
pathic effect of influenza infection. As a consequence, the
hits identified by pooled RNAi screen may be different
from those obtained by arrayed siRNA screen. Points to
consider when evaluating the pooled screen versus the
arrayed screen include: (i) the negative factors for influ-
enza replication, as well as anti-apoptotic factors for cell
signaling cannot be selected by pooled RNAi screen/selec-
tion due to accelerated removal of virus-infected cells,
while both positive and negative factors can be identified
by arrayed siRNA screen; (ii) host factors essential for cell
survival or cell proliferation required for influenza replica-
tion are excluded from the list of hits during long-term
gene silencing; accordingly, the hits (genes) identified by
pool selection are potentially more suitable as drug targets
because they are required for influenza replication without















Hao et al. (2008) [2] 11 5 6 10 3 6
Brass et al. (2009) [3] 16 9 11 5 9
Shapira et al. (2009) [4] 12 12 7 24
Kŏnig et al. (2010) [5] 25 7 7
Karlas et al. (2010) [6] 6 4
Su et al. (2013) [7] 4
Tran et al. (2013) [9]
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based RNAi screen provides an advantage in identification
of host factors/proteins with long half-life, which might
not be identified by siRNA transient transfection ap-
proach; (iv) cellular apoptotic factors would be easily se-
lected out during positive selection since knockdown of
these apoptotic genes will make cells more resistant to
IAV-induced apoptosis; some of the selected cellular apop-
totic factors may not be directly involved in influenza rep-
lication. In conclusion, performing screens using different
approaches, such as various detection methods/parame-
ters (i.e., RNA replication versus whole viral life cycle) and
RNAi reagents (i.e., siRNA versus shRNA, or different
siRNA libraries), should increase the chance of discovering
essential host factors. Therefore, the gene lists from differ-
ent screens should be able to complement each other.
The optimal concentration of siRNA used for gene si-
lencing varies (1–30 nM) from study to study, and is
highly dependent on the cell type and its target. Trans-
fection of siRNA by using improper concentrations of
siRNAs may result in unwanted off-target effects or in-
complete gene silencing during arrayed siRNA screens,
which may produce misleading results. It may be diffi-
cult to determine an optimal siRNA concentration for
performing an arrayed siRNA screen. On the contrary,
pooled shRNA screens take advantage of lentiviral trans-
duction at low MOI (usually between 0.1–0.3) to deliver
single copy of shRNA into cells. This low MOI remarkably
reduces the probability of off-target effects. However, het-
erogeneity of functional siRNAs may be generated by
improper processing of a shRNA hairpin, thus causing off-
target effects. To minimize the off-target effects in both
cases, targeted genes knocked down by at least 2 unique
siRNAs (or shRNAs), which target different regions within
the same gene transcript are recommended as the selec-
tion criteria, since the probability of off-target effects trig-
gered by 2 independent siRNAs (or shRNAs) to the same
target gene is extremely low. Unfortunately, the knock-
down efficiency of individual siRNA in a given arrayed
smart pool RNAi library is usually not known although
the manufacturer guarantees that at least one of the pro-
vided siRNAs has good knockdown efficiency of 70% ormore. Such knockdown information is less informative for
researchers who intend to minimize the off-target effects
by using two good individual siRNAs. By contrast, more
than 40% of the shRNAs from the TRC RNAi library have
been validated and the knockdown information of these
shRNAs would provide great advantage for analysis of pri-
mary hits.
Other factors involved in genome-wide pooled shRNA
screen/selection
Genome-wide pooled shRNA screens are technically
complicated, and numerous factors directly or indirectly
affect the efficiency and accuracy of the screening re-
sults. Several experimental details have to be taken into
consideration when performing a large-scale pooled RNAi
screen. First, individual shRNA (shRNA-expressing lenti-
virus) should be enlarged to more than 250 representatives
to guarantee that the effective shRNA(s) is not lost in sub-
sequent experimental procedures and to compensate for
the low expression level resulting from random integra-
tion sites of the shRNA expression cassette [18]. Second,
an MOI of shRNA-expressing lentivirus at 0.1-0.3 is rec-
ommended to ensure that most of the surviving cells
under puromycin selection receive only one copy of
shRNA (one lentivirus) [18]. Reducing the MOI is not rec-
ommended, as further reduction of MOI only slightly re-
duces the probability of a cell being infected by two or
more viruses, but significantly increases the number of
cells needed for transducing the pooled shRNA lentivi-
ruses (our unpublished data).
Third, when performing a pooled RNAi screen, the
use of polybrene (hexadimethrine bromide) during lenti-
virus transduction should be avoided. Polybrene is a
common polycation that increases the infectivity of
lentivirus 3–5 fold (our unpublished data). The cationic
polymer enhances virus adsorption and transduction by
neutralizing the charge between viral envelope and cellu-
lar membrane [19]. Moreover, polybrene has the poten-
tial to facilitate virus aggregation which increases the
possibility of multiple virus infection during the pooled
RNAi screen. By using lentivirus carrying EGFP fluores-
cence or mCherry fluorescence, we mimicked a pooled
Chou et al. Journal of Clinical Bioinformatics  (2015) 5:2 Page 7 of 9screening and showed that the proportions of EGFP
(+)/mCherry(+) cells in the presence or absence of
polybrene were 13.6% and 8.5%, respectively (Figure 1,
MOI = 0.3). Assuming that the probability of cells infected
by multiple lentiviruses expressing EGFP or mCherry
alone is, at most, half the value of EGFP/mCherry, the
probability of multiple infections in the whole population
would be equal or less than 27.2% and 17% in the presence
or absence of polybrene, respectively. It should also be
noted that the theoretical value (calculated by the Poisson
distribution equation) of multiple virus infections in the
condition of MOI 0.3 is 14.3%, which is very close to the
actual proportion of multiple virus infection (17%) in per-
forming a pooled lentivirus infection without polybrene.
This result demonstrates that the use of polybrene aug-
ments the proportion of multiple virus infection by at least
1.5 fold, suggesting that the use of polybrene in the pooled
RNAi screen may cause multiple virus infection and thus
increase the noise of hits.
Unlike the arrayed RNAi screen, the potential hits (the
content of shRNAs) selected/enriched by a pooled RNAi
screen must be further identified by other methods, such
as barcode microarray or next generation sequencingFigure 1 Effect of polybrene in multiple virus infection. A549 cells wer
fluorescent gene. Lentivirus infection was performed by spin infection with
8 μg/ml polybrene (MOI = 0.2 or 0.3). Twenty four hours later, the culture med
After puromycin selection for 5 days, the proportion of cells with EGFP(+)/mC
signals were analyzed by flow cytometry.(NGS). The barcode microarray-based method employs
PCR amplification of shRNA template sequence pools,
labeling of fluorophore, and hybridization to comple-
mentary DNA microarray chip(s) from an experimental
group as well as a reference group. After hybridization,
the fluorescent signal intensity reflects the abundance of
cells expressing a certain shRNA under test conditions
as compared to the reference. However, the dissimilar
amplification resulting from self-annealing of hairpin se-
quences of shRNA may cause detection bias during
microarray analysis. The external barcode tags help to
optimize hybridization conditions for each probe and
avoid technique bias of PCR amplification caused by the
secondary structures of the shRNA template sequence.
Artifacts caused by cross-hybridization, also known as
unspecific probe-target interaction, are the major con-
cern of barcode microarray hybridization in identifica-
tion of target shRNA from genome-wide pooled RNAi
screen. NGS or namely deep sequencing technology pro-
vides a new approach for the analysis of the hits selected
by pooled RNAi screens. In brief, the experimental pro-
cedure of NGS consists of: (i) isolation of genomic DNA;
(ii) PCR amplification of shRNA; (iii) restriction enzymee transduced with a 1:1 ratio of lentiviruses carrying EGFP or mCherry
centrifugation at 1100 × g for 30 min in the presence or absence of
ium was replaced with fresh F-12 K medium with 2 μg/ml puromycin.
herry(−), EGFP(+)/mCherry(+) and EGFP (−)/mCherry(+) fluore-scence
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(iv) ligation of PCR products to an adaptor for subsequent
NGS analysis. In general, maintaining the fidelity of
shRNA population during preparation of PCR fragments
for NGS is important for subsequent hit determination.
Our recommendations for preparing shRNA-containing
PCR fragments for NGS are as follows: (i) Prepare appro-
priate amounts of genomic DNA without loss of shRNA
complexity. Low amounts of genomic DNA may not cover
the whole population of shRNA in a typically genome-
wide-scale negative selection experiment; (ii) Avoid creat-
ing conditions that generate sequencing bias during PCR
amplification, such as over-amplification and two-rounds
of PCR. Exponential PCR cycles without generating het-
eroduplex that are derived from annealing of two shRNA
sequences occurring at the later stage of PCR are recom-
mended; (iii) Prepare PCR fragments with half-arm of
shRNA cassette for NGS, if possible, because full-length
shRNA may impede sequencing; (iv) Templates should
contain a 5' end phosphate and a 3' end hydroxyl group
for efficiently adding adaptor for NGS; (v) Purify restricted
PCR fragments by gel electrophoresis for deep sequencing.
A protocol for genome-wide pooled RNAi screen can be
found at: http://rnai.genmed.sinica.edu.tw/file/protocol/
PooledScreen_SequencingProtocol.pdf.
By detection of the amounts of the shRNA sequence,
the NGS approach may hold greater promise for accur-
acy than that of the barcode microarray-based method
for deconvolution of genome-wide pooled RNAi screen-
ing output. There are at least four advantages of using
the NGS method in place of the barcode microarray
hybridization. First, NGS technology is a cost-effective
approach because it measures the presence of large
quantities of distinct shRNA sequences in a short time.
Secondly, NGS greatly improves the sensitivity and effi-
cacy of detection by offering a digital readout of even
very small amounts of shRNA species. Third, the NGS
method provides a greater detection range and better
resolution of measurements, which enables clear dis-
crimination of true hits from background noise. Finally,
NGS is a more flexible approach for the identification of
hits from a genome-wide RNAi screen, which can be
easily incorporated into any high-complexity shRNA li-
brary without generating new information of barcode
and linkage to individual shRNA sequence.
Conclusions and perspectives
Genome-wide RNAi screen is a useful tool for studying
the gene functions by manipulation of gene expression.
Both arrayed RNAi screen and pooled RNAi screen have
been successfully conducted to identify host factors crucial
for influenza virus replication. Two previous influenza
screening reviews focusing on arrayed RNAi screens have
uncovered host factors and cellular networks involved inthe influenza virus replication [20,21]. Here, we review the
current genome-wide influenza screens; both arrayed
RNAi screens and pooled RNAi screens. A comparison of
the published genome-wide RNAi screens of influenza re-
search (2008–2013) revealed that only a limited number
of overlapping hits were identified among these RNAi
screens, and such an inconsistency is very likely due to the
different screening approaches/ methods used. Overall,
there was zero commonality among the seven different
RNAi screens to identify host factors for influenza virus
infection. This result is consistent with previous genome-
wide RNAi screens that searched for host targets to com-
bat HIV infection (2008–2011), in which there was zero
gene commonality across the board [22-27]. Although
overlapping genes were found among some of the screens,
the reason why an essential host gene identified in one
screen could not be fully reproduced in the others remains
unknown. It is very likely because different experimental
parameters were used in each screen, which may directly
or indirectly affect the efficiency and accuracy of the
RNAi-based screening. Moreover, the analyzed time points
covered by the different strategies of RNAi screens, e.g.,
short-term knockdown by siRNA or long-term knock-
down by lentivirus-based shRNA, also influence the popu-
lations of host factors identified by the RNAi screens.
Other factors, e.g., the genes involved in shRNA process-
ing, may also result in the biased selection of candidate
genes in different RNAi screens. As a consequence, the
different features of the arrayed siRNA screen and the
pooled shRNA screen should be taken into consideration
while designing a feasible genome-wide RNAi screen pro-
cedure. Here, we have shown several benefits as well as
tips in performing genome-wide pooled shRNA screens.
Although there are still some concerns about pooled
shRNA screens, these concerns can be technologically
overcome through careful design of the screening proce-
dures, use of proper controls and stringent standards for
identification of the hits. In combination with the ad-
vances in NGS technology, the genome-wide pooled
shRNA screen can thus be hailed as the second genomics
wave.
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